Milestone Pharmaceuticals Inc. develops and commercializes cardiovascular medicines, centered on CARDAMYST (etripamil) nasal spray. CARDAMYST is FDA-approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia, or PSVT, to sinus rhythm in adults. Etripamil is also being developed for symptomatic episodic attacks associated with AFib-RVR.
Company news commonly covers CARDAMYST commercialization, payer formulary access, real-world evidence work such as the RESET-PSVT registry, cardiovascular conference presentations, regulatory updates, financial results and business updates. Milestone also reports equity inducement grants and other corporate actions tied to its Nasdaq-listed common shares.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) announced participation at the 22nd Annual Needham Virtual Healthcare Conference on April 19, 2023, at 3:45 p.m. ET. The live presentation will be available via webcast on the company's website.
Milestone focuses on innovative cardiovascular medicines, with its lead product candidate, etripamil, having recently completed a Phase 3 clinical program for treating paroxysmal supraventricular tachycardia (PSVT). It is also in a Phase 2 trial for atrial fibrillation with rapid ventricular rate (AFib-RVR). The company operates in both Canada and the United States.